GUFIC BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 311.8 INR | -0.49% |
|
-0.84% | -1.16% |
| May. 30 | Transcript : Gufic Biosciences Limited, Q4 2024 Earnings Call, May 30, 2024 | |
| May. 29 | Gufic Biosciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 7.79B 93.41M | Sales 2023 | 6.91B 82.79M | Capitalization | 18.09B 217M |
|---|---|---|---|---|---|
| Net income 2022 | 958M 11.48M | Net income 2023 | 797M 9.55M | EV / Sales 2022 | 3.16 x |
| Net Debt 2022 | 528M 6.33M | Net Debt 2023 | 3.06B 36.63M | EV / Sales 2023 | 3.06 x |
| P/E ratio 2022 |
25.2
x | P/E ratio 2023 |
22.7
x | Employees | 1,628 |
| Yield 2022 |
0.04% | Yield 2023 |
0.05% | Free-Float | 22.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gufic Biosciences Limited
More recommendations
| 1 day | -0.49% | ||
| 1 week | -0.84% | ||
| Current month | +1.28% | ||
| 1 month | -4.47% | ||
| 3 months | +3.76% | ||
| 6 months | -5.86% | ||
| Current year | -1.16% |
1 week
278.00
317.45
1 month
278.00349.00
Current year
278.00364.00
1 year
195.25364.00
3 years
170.20364.00
5 years
37.55364.00
10 years
7.25364.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 41 | 04-06-24 | |
| Chief Executive Officer | - | 99-08-30 | |
| Director of Finance/CFO | - | 18-10-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 99-08-30 | |
| Chief Executive Officer | 41 | 04-06-24 | |
| Director/Board Member | 65 | 86-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 311.8 | -0.49% | 6,286 |
| 24-06-05 | 313.4 | +6.22% | 6,638 |
| 24-06-04 | 295 | -6.14% | 11,596 |
| 24-06-03 | 314.4 | +2.09% | 3,964 |
| 24-05-31 | 307.9 | -2.10% | 11,568 |
Delayed Quote Bombay S.E., June 06, 2024 at 06:00 am EDT
More quotes
Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates through the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.16% | 377M | |
| +43.64% | 749B | |
| +39.42% | 605B | |
| -6.58% | 351B | |
| +19.72% | 328B | |
| +8.78% | 292B | |
| +11.92% | 216B | |
| -2.62% | 214B | |
| +0.03% | 167B | |
| +6.13% | 165B |
- Stock Market
- Equities
- GUFICBIO Stock
